Skip to main content

Table 4 Antimicrobial resistance of Acinetobacter baumannii and Pseudomonas aeruginosa isolates to the tested antibiotics

From: Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital

Resistance rate (%)

Isolate/Antibiotics

2008–2011

2012–2015

Total

P for Trend Test

Acinetobacter baumannii

 AMP

96.43

100.00

98.55

0.223

 SAM

90.48

100.00

96.77

0.045

 TZP

96.30

95.00

95.52

0.801

 SXT

95.24

73.17

80.65

0.037

 CRO

94.44

100.00

98.31

0.128

 CTX

100.00

100.00

100.00

–

 CAZ

88.89

100.00

95.59

0.029

 FEP

96.30

100.00

98.53

0.214

 IPM

96.30

95.12

95.59

0.818

 LVX

66.67

56.10

60.29

0.383

 CIP

95.24

97.56

96.77

0.624

Pseudomonas aeruginosa

 AMK

31.82

22.22

25.86

0.418

 SAM

100.00

100.00

100.00

–

 TZP

60.87

33.33

44.07

0.038

 ATM

58.82

75.00

61.90

0.549

 SXT

100.00

97.22

98.11

0.488

 CRO

100.00

100.00

100.00

–

 CTX

100.00

100.00

100.00

–

 CAZ

69.57

61.11

64.41

0.508

 FEP

65.22

50.00

55.93

0.251

 IPM

73.91

58.33

64.41

0.223

 LVX

34.78

44.44

40.68

0.461

 CIP

38.89

41.18

40.38

0.873

Not all tested antibiotics are listed

  1. AMK Amikacin, SAM Ampicillin/Sulbactam, TZP piperacillin-tazobactam, ATM Aztreonam, SXT Trimethoprim/Sulfamethoxazole, CRO Ceftriaxone, CTX cefotaxime, CAZ ceftazidime, FEP cefepime, IPM imipenem, LVX levofloxacin, CIP ciprofloxacin
  2. Data in boldface reflected p values < 0.05